ClinicalTrials.gg

Program

bosmolisib

Also written as “BR101801”, “BR101801 (Phase Ia)” and “BR101801 (Phase Ib)”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Lymphoma, Large B-Cell, Diffuse, led by Boryung Pharmaceutical.

Furthest: phase 2, since Sep 4, 20252 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boryung Pharmaceutical21 open or runningphase 2since Sep 4, 2025Jun 14, 2019Sep 2027phase 2 · NCT07180771

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 14, 2019First study: phase 1 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT04018248 · 26 enrolled · United States, South Korea
  2. Sep 4, 2025Phase 2 study in Lymphoma, T-Cell, PeripheralNCT07180771 · 44 planned

Ahead

  1. Sep 2027Primary completion: phase 2 study in Lymphoma, T-Cell, PeripheralNCT07180771

TargetBeta

PRKDC →read by rule
“An orally bioavailable inhibitor of phosphoinositide 3-kinase delta (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta) and DNA-dependent protein kinase (DNA-PK), ”NCIt, by rule

Other programs on PRKDC

ProgramCompanyFurthest phaseStudies
AMO959Novartisphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07180771Lymphoma, T-Cell, Peripheral2Not yet recruitingSep 202744
NCT04018248Lymphoma, Large B-Cell, Diffuse · United States, South Korea1CompletedSep 21, 202326

How it is read

Names in the registry

  • “BR101801”, 1 entry
  • “BR101801 (Phase Ia)”, 1 entry
  • “BR101801 (Phase Ib)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.